Holen Sie sich die Stockscreener-App
6.11
0.97%
-0.06
Handel nachbörslich:
6.16
0.05
+0.82%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.17
Offen:
$6.17
24-Stunden-Volumen:
883.42K
Relative Volume:
0.54
Marktkapitalisierung:
$473.62M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-2.0099
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
-2.86%
1M Leistung:
+13.36%
6M Leistung:
+51.61%
1J Leistung:
-31.58%
1-Tages-Spanne:
$6.02
$6.255
1-Wochen-Bereich:
$5.75
$6.8075
52-Wochen-Spanne:
$2.41
$10.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.11 | 478.27M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-26 | Eingeleitet | Citigroup | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-13 | Eingeleitet | Wedbush | Outperform |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | William Blair | Outperform |
| 2024-03-15 | Eingeleitet | Citigroup | Buy |
| 2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-05-27 | Eingeleitet | Jefferies | Buy |
| 2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
| 2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
| 2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | Eingeleitet | Citigroup | Sell |
| 2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Is Solid Biosciences Inc. stock a good pick for beginnersJuly 2025 Market Mood & Weekly Return Optimization Alerts - thegnnews.com
Why Solid Biosciences Inc. stock attracts strong analyst attentionJuly 2025 Spike Watch & Fast Entry High Yield Stock Tips - beatles.ru
Is now the right time to enter Solid Biosciences Inc.Market Growth Summary & AI Powered Trade Plan Recommendations - sundaytimes.kr
Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces pivotal year - Investing.com
Citi Maintains Buy Rating on Solid Biosciences with $16 Price Target - AInvest
Citizens JMP Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
J.P. Morgan Sticks to Their Buy Rating for Solid Biosciences (SLDB) - The Globe and Mail
SLDB’s Stock Market Adventure: -9.49% YTD Growth Amidst Volatility - investchronicle.com
JMP reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Can Solid Biosciences Inc. recover in the next quarter2025 Growth vs Value & Weekly Market Pulse Updates - Newser
40,930 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Purchased by XTX Topco Ltd - Defense World
Solid Biosciences (NASDAQ:SLDB) Shares Up 9.9% Following Strong Earnings - Defense World
Smart tools for monitoring Solid Biosciences Inc.’s price actionWeekly Volume Report & Weekly High Conviction Ideas - Newser
Is Solid Biosciences Inc. stock overhyped or has real potentialOptions Play & Real-Time Market Sentiment Alerts - Newser
Developing predictive dashboards with Solid Biosciences Inc. data2025 Price Targets & Long-Term Capital Growth Strategies - Newser
What institutions are buying Solid Biosciences Inc. stock nowJuly 2025 Action & Fast Momentum Stock Entry Tips - Newser
Wedbush Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
William Blair Maintains Buy Rating for Solid Biosciences, Raises Price Target to $15.44. - AInvest
A Quick Look at Today's Ratings for Solid Biosciences(SLDB.US), With a Forecast Between $10 to $20 - 富途牛牛
Solid Biosciences: Promising Developments and Financial Stability Drive Buy Rating - TipRanks
Solid Biosciences Reports Increased Assets Amid Ongoing Losses - TipRanks
How Solid Biosciences Inc. stock performs during market volatilitySecure Entry Point Finder with Analysis - Newser
Solid Biosciences shares rise 2.81% after-hours following Anixa Biosciences' patent extension to 2045. - AInvest
SOLID BIOSCIENCES Earnings Results: $SLDB Reports Quarterly Earnings - Quiver Quantitative
Solid Biosciences Pushes Forward Despite Growing Losses - Finimize
Solid Biosciences Q2 net loss widens to $39.5 mln - MarketScreener
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Solid Biosciences Inc. Reports Progress in Clinical Trials and Financial Highlights for Q2 2025 - Quiver Quantitative
How to read the order book for Solid Biosciences Inc.Market Forecast Summary Over Multi-Year Period - Newser
Applying big data sentiment scoring on Solid Biosciences Inc.Momentum Prediction Based on AI Backtesting - Newser
Risk adjusted return profile for Solid Biosciences Inc. analyzedStock Market Watch with Smart Filters - Newser
Solid Biosciences Inc. stock trend forecastFree Earnings Play Trade Plan With Alerts - Newser
Wyckoff Accumulation Phase Possible in Solid Biosciences Inc.Breakout Momentum Picks With Protection Outlined - beatles.ru
Key resistance and support levels for Solid Biosciences Inc.Volume Confirmed Setup with Entry Confidence - Newser
Solid Biosciences (SLDB) Projected to Post Quarterly Earnings on Tuesday - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences SLDB 2025Q2 Earnings Preview Upside Potential on Strategic Developments - AInvest
Will Solid Biosciences Inc. rebound enough to break evenPrice Movement and Market Sentiment Analysis - Newser
Applying Elliott Wave Theory to Solid Biosciences Inc.Chart Pattern Recognition for Profit Timing - Newser
Solid Biosciences Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
How hedge fund analytics apply to Solid Biosciences Inc. stockSwing Entry Risk Mitigation with Chart Analysis - Newser
Allianz Asset Management GmbH Purchases Shares of 27,100 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Inc. shares rise 1.03% after-hours following Wall Street's recovery from jobs report-fueled losses. - AInvest
What is the dividend policy of Solid Biosciences Inc. stockGet timely alerts on market opportunities - Jammu Links News
Should I hold or sell Solid Biosciences Inc. stock in 2025Discover stocks with massive upside potential - Jammu Links News
How strong is Solid Biosciences Inc. company’s balance sheetGet daily expert analysis for smarter investing - Jammu Links News
What are the latest earnings results for Solid Biosciences Inc.Robust investment performance - Jammu Links News
Is Solid Biosciences Inc. stock overvalued or undervaluedAchieve rapid returns with smart investment plans - Jammu Links News
What catalysts could drive Solid Biosciences Inc. stock higher in 2025Track top-performing stocks effortlessly - Jammu Links News
What drives Solid Biosciences Inc. stock priceConsistent double returns - Jammu Links News
Solid Biosciences Inc. Stock Analysis and ForecastIdentify undervalued stocks poised to rally - Jammu Links News
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Solid Biosciences Inc-Aktie (SLDB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):